QLGN - MCAP CO - Qualigen Therapeutics

Qualigen Therapeutics generates revenue from the sale of rapid blood tests and plans to expand profits through new cancer and antiviral drugs. This chart illustrates that the asset's market value is , highlighting the potential of strategic alliances with scientists to create innovative molecules and attract buyers. Meanwhile, partner plants are configuring high-precision equipment for the current stages of clinical trials.

The development of innovative methods to combat oncology and viruses determines the market value of Qualigen Therapeutics (QLGN). By analyzing the issuer's capitalization level, an investor sees the aggregate value of all the company's shares. This indicator is calculated as the product of the current share price and the total number of issued securities. The metric's dynamics reflect the market's confidence in the success of the biotechnological platforms. The stability of this value confirms the business's resilience to macroeconomic shocks.